Elixir Medical Corporation: EuroPCR 2023: Late-Breaking Clin

First head-to-head randomized clinical trial (RCT) of DynamX Bioadaptor compared to Resolute Onyx DES shows statistically significant effectiveness in restoring vessel pulsatility, achieving significantly

Related Keywords

United States , Milpitas , California , Erich Sandoval , Gewinn Nur , Motasim Sirhan , Linkedin , Twitter , Elixir Medical Corporation , Development Of The Dynamx Bioadaptorthe , Dynamx Bioadaptor , Resolute Onyx , Target Lesion Failure , Drug Eluting Bioadaptor , Eluting Stent , Clinical Safety , Efficacy Results , Device Effectiveness , Vessel Function Results , Plaque Stabilization , Dynamx Bioadaptorthe , Elixir Medical , Dynamx Coronary Bioadaptor System , Medical Corporation , Elixir , Medical , Corporation , Uropcr , 023 , Gate , Breaking , Linical , Data , Emonstrate , Ynamx , Ioadaptor , Restores , Vessel , Lotion , Junction , Setter , Effectiveness , Months , Ompared , Reading , Drug ,